192 related articles for article (PubMed ID: 21969595)
1. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.
Choi PS; van Riggelen J; Gentles AJ; Bachireddy P; Rakhra K; Adam SJ; Plevritis SK; Felsher DW
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17432-7. PubMed ID: 21969595
[TBL] [Abstract][Full Text] [Related]
2. Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance.
Choi PS; Li Y; Felsher DW
Proc Natl Acad Sci U S A; 2014 Aug; 111(32):E3316-24. PubMed ID: 25071175
[TBL] [Abstract][Full Text] [Related]
3. Expression of lymphomagenic oncogenes in T-cell lymphomas of HPV 16 transgenic mice.
Yang JT; Liu CZ; Domer P; Iannaccone P
Cancer Detect Prev; 1998; 22(5):405-15. PubMed ID: 9727621
[TBL] [Abstract][Full Text] [Related]
4. Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia.
Mahauad-Fernandez WD; Rakhra K; Felsher DW
Methods Mol Biol; 2021; 2318():297-312. PubMed ID: 34019298
[TBL] [Abstract][Full Text] [Related]
5. p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia.
Yetil A; Anchang B; Gouw AM; Adam SJ; Zabuawala T; Parameswaran R; van Riggelen J; Plevritis S; Felsher DW
Oncotarget; 2015 Feb; 6(6):3563-77. PubMed ID: 25784651
[TBL] [Abstract][Full Text] [Related]
6. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.
Tran PT; Fan AC; Bendapudi PK; Koh S; Komatsubara K; Chen J; Horng G; Bellovin DI; Giuriato S; Wang CS; Whitsett JA; Felsher DW
PLoS One; 2008 May; 3(5):e2125. PubMed ID: 18461184
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Ras, Raf and L-myc but not Bcl-2 family proteins is linked with resistance to TCR-mediated apoptosis and tumorigenesis in thymic lymphomas from TCR transgenic mice.
Kobzdej M; Matuszyk J; Strzadala L
Leuk Res; 2000 Jan; 24(1):33-8. PubMed ID: 10634643
[TBL] [Abstract][Full Text] [Related]
8. High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.
Chiang MY; Wang Q; Gormley AC; Stein SJ; Xu L; Shestova O; Aster JC; Pear WS
Blood; 2016 Nov; 128(18):2229-2240. PubMed ID: 27670423
[TBL] [Abstract][Full Text] [Related]
9. Conditional expression and oncogenicity of c-myc linked to a CD2 gene dominant control region.
Stewart M; Cameron E; Campbell M; McFarlane R; Toth S; Lang K; Onions D; Neil JC
Int J Cancer; 1993 Apr; 53(6):1023-30. PubMed ID: 8473043
[TBL] [Abstract][Full Text] [Related]
10. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
Elson A; Deng C; Campos-Torres J; Donehower LA; Leder P
Oncogene; 1995 Jul; 11(1):181-90. PubMed ID: 7624126
[TBL] [Abstract][Full Text] [Related]
11. Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice.
Baxter EW; Blyth K; Cameron ER; Neil JC
J Virol; 2001 Oct; 75(20):9790-8. PubMed ID: 11559812
[TBL] [Abstract][Full Text] [Related]
12. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
13. MYC fails to efficiently shape malignant transformation in T-cell acute lymphoblastic leukemia.
Loosveld M; Bonnet M; Gon S; Montpellier B; Quilichini B; Navarro JM; Crouzet T; Goujart MA; Chasson L; Morgado E; Picard C; Hernandez L; Fossat C; Gabert J; Michel G; Nadel B; Payet-Bornet D
Genes Chromosomes Cancer; 2014 Jan; 53(1):52-66. PubMed ID: 24249258
[TBL] [Abstract][Full Text] [Related]
14. Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging.
Blyth K; Terry A; Mackay N; Vaillant F; Bell M; Cameron ER; Neil JC; Stewart M
Oncogene; 2001 Jan; 20(3):295-302. PubMed ID: 11313958
[TBL] [Abstract][Full Text] [Related]
15. Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia.
Demarest RM; Dahmane N; Capobianco AJ
Blood; 2011 Mar; 117(10):2901-9. PubMed ID: 21217079
[TBL] [Abstract][Full Text] [Related]
16. Selection for c-myc integration sites in polyclonal T-cell lymphomas.
Broussard DR; Mertz JA; Lozano M; Dudley JP
J Virol; 2002 Mar; 76(5):2087-99. PubMed ID: 11836386
[TBL] [Abstract][Full Text] [Related]
17. Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1.
Li X; Gounari F; Protopopov A; Khazaie K; von Boehmer H
J Exp Med; 2008 Nov; 205(12):2851-61. PubMed ID: 18981238
[TBL] [Abstract][Full Text] [Related]
18. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.
Sanchez-Martin M; Ferrando A
Blood; 2017 Mar; 129(9):1124-1133. PubMed ID: 28115368
[TBL] [Abstract][Full Text] [Related]
19. Reversible lymphomagenesis in conditionally c-MYC expressing mice.
Marinkovic D; Marinkovic T; Mahr B; Hess J; Wirth T
Int J Cancer; 2004 Jun; 110(3):336-42. PubMed ID: 15095297
[TBL] [Abstract][Full Text] [Related]
20. Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: dose dependence and involvement of myc and ras.
Breuer M; Wientjens E; Verbeek S; Slebos R; Berns A
Cancer Res; 1991 Feb; 51(3):958-63. PubMed ID: 1988138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
